Value of cystatin C in the diagnosis of early renal injury in patients with viral hepatitis
-
摘要: 目的探讨血清胱抑素C(Cys C)检测在病毒性肝炎早期肾损伤诊断中的意义。方法回顾性分析2018年1月1日-2018年12月31日西安交通大学第一附属医院270例慢性HBV感染及HCV感染者临床资料,按FibroScan检测的肝纤维化程度分为4组:无明显肝纤维化组(F0~F2)、明显肝纤维化组(F2~F3)、进展性肝纤维化组(F3~F4)、肝硬化组(> F4),比较各组尿素氮、肌酐、Cys C及估算的肾小球滤过率(eGFR)水平差异。计量资料2组间比较采用t检验;多组间比较采用单因素方差分析,进一步两两比较采用LSD-t检验。相关性检验使用Pearson相关分析。结果 270例患者中,HBV感染者200例,HCV感染者70例。eGFR及Cys C水平在4组中差异均有统计学意义(F值分别为2. 714、3. 081,P值分别为0. 032、0. 017)。进一步两两比较,肝硬化组的eGFR低于无明显纤维化组[(99. 61±6. 92) ml·min-1·1. 73 m-2vs (105. 32±1. 86) ml·min-1<...Abstract: Objective To investigate the value of serum cystatin C( Cys C) in the diagnosis of early renal injury in patients with viral hepatitis. Methods A retrospective analysis was performed for the clinical data of 270 patients with chronic hepatitis B virus( HBV) or hepatitis C virus( HCV) infection. According to the fibrosis degree determined by FibroScan,the patients were divided into non-significant liver fibrosis group( F0-F2),significant liver fibrosis group( F2-F3),progressive liver fibrosis group( F3-F4),and liver cirrhosis group( >F4). The four groups were compared in terms of urea nitrogen,creatinine,Cys C,and estimated glomerular filtration rate( e GFR). The t-test was used for comparison of continuous data between two groups; a one-way analysis of variance was used for comparison between multiple groups,and the least significant difference t-test was used for further comparison between two groups. A Pearson correlation analysis was used to investigate correlation. Results Among the 270 patients,200 had HBV infection and 70 had chronic HCV infection. There were significant differences in e GFR and Cys C between the four groups( F = 2. 714 and 3. 081,P = 0. 032 and 0. 017). Further comparison between two groups showed that the liver cirrhosis group had a significantly lower eGFR than the non-significant liver fibrosis group( 99. 61 ± 6. 92 ml·min-1·1. 73 m-2 vs 105. 32 ± 1. 86 ml·min-1·1. 73 m-2,t = 2. 655,P = 0. 008); compared with the non-significant liver fibrosis group,the other three groups had significant increases in the serum level of Cys C( significant liver fibrosis group: 1. 01 ± 0. 08 mg/L vs 0. 84± 0. 03 mg/L,t =-2. 218,P = 0. 028; progressive liver fibrosis group: 1. 02 ± 0. 04 mg/L vs 0. 84 ± 0. 03 mg/L,t =-4. 218,P < 0. 001;liver cirrhosis group: 1. 07 ± 0. 05 mg/L vs 0. 84 ± 0. 03 mg/L,t =-4. 675,P < 0. 001). For the patients with HBV or HCV infection,the patients with liver cirrhosis had a significantly higher serum level of Cys C than those without significant liver fibrosis( patients with HBV infection: 1. 06 ± 0. 36 mg/L vs 0. 84 ± 0. 13 mg/L,t =-3. 192,P = 0. 003; patients with HCV infection: 1. 04 ± 0. 22 mg/L vs 0. 86 ± 0.15 mg/L,t =-2. 318,P = 0. 029). Liver stiffness measurement was positively correlated with the serum level of Cys C( r = 0. 247,P = 0.003),while there was no correlation between liver stiffness measurement and eGFR( r =-0. 002,P = 0. 975). Conclusion Cys C can be used for the diagnosis of early renal injury in patients with viral hepatitis,and regular monitoring of Cys C level has a positive significance in the prevention and treatment of hepatorenal syndrome in such patients.
-
Key words:
- hepatitis B,chronic /
- hepatitis C,chronic /
- liver cirrhosis /
- kidney injury
-
[1] LI D,GAO G,JIANG H,et al. Hepatitis B virus-associated glomerulonephritis in HBsAg serological-negative patients[J]. Eur J Gastroenterol Hepatol,2015,27(1):65-69. [2] GOEL A,BHADAURIA DS,KAUL A,et al. Experience with direct acting anti-viral agents for treating hepatitis C virus infection in renal transplant recipients[J]. Indian J Gastroenterol,2017,36(2):137-140. [3] GILL K,GHAZINIAN H,MANCH R,et al. Hepatitis C virus as a systemic disease:Reaching beyond the liver[J]. Hepatol Int,2016,10(3):415-423. [4] PAPASSOTIRIOU GP,KASTRITIS E,GKOTZAMANIDOU M,et al.Neutrophil gelatinase-associated lipocalin and cystatin C are sensitive markers of renal injury in patients with multiple myeloma[J]. Clin Lymphoma Myeloma Leuk,2016,16(1):29-35. [5] SHAH N,SILVA RG,KOWALSKI A,et al. Hepatorenal syndrome[J]. Dis Mon,2016,62(10):364-375. [6] TANG S,LAI FM,LUI YH,et al. Lamivudine in hepatitis Bassociated membranous nephropathy[J]. Kidney Int,2005,68(4):1750-1758. [7] ABU Y,MUSSA S,NAIK MJ,et al. Evaluation of cystatin C as a marker of renal injury following on-pump and off-pump coronary surgery[J]. Eur J Cardiothorac Surg,2005,27(5):893-898. [8] ZHAO P,ZHAO J,TIAN JP,et al. Detection of biomarkers in patients with sepsis complicated with acute kidney injury and its relationship with renal artery resistance index[J]. J Clin Exp Med,2019,18(7):730-733.(in Chinese)赵鹏,赵娟,田静朴,等.脓毒症合并急性肾损伤患者生物学标志物检测及其与肾动脉阻力指数的关系[J].临床和实验医学杂志,2019,18(7):730-733. [9] WEN LL,LIANG CB. Influence of high-flux hemodialysis on serum factors and short-term prognosis of patients with chronic renal failure with uremia[J]. Clin J Med Offic,2019,47(4):354-359.(in Chinese)温莉玲,梁春波.高通量血液透析对慢性肾功能衰竭尿毒症患者血清因子及近期预后影响[J].临床军医杂志,2019,47(4):354-359.
本文二维码
计量
- 文章访问数: 1192
- HTML全文浏览量: 28
- PDF下载量: 268
- 被引次数: 0